Гастроинтестинальные стромальные опухоли: что нового в терапии?

Гастроинтестинальные стромальные опухоли: что нового в терапии?

Автор: Корнилова Ануш Григорьевна, Когония Лали Михайловна, Мазурин Валентин Сергеевич, Морданов Сергей Викторович, Оксенюк Оксана Станиславовна

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Обзоры

Статья в выпуске: 2 (68), 2015 года.

Бесплатный доступ

Обзор литературы посвящен анализу методов лечения гастроинтестинальных стромальных опухолей с момента выделения этой патологии в отдельную нозологическую единицу до настоящего времени. Представлены современные тенденции таргетной терапии ГИСО.

Гастроинтестинальные стромальные опухоли, таргетная терапия

Короткий адрес: https://sciup.org/14056773

IDR: 14056773

Список литературы Гастроинтестинальные стромальные опухоли: что нового в терапии?

  • Benjamin R.S., Rankin C., Fletcher C. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: intergroup S0033 early results//Proc. ASCO. 2003. № 22. P. 3271.
  • Blanke C.D., Demetri G.D., von Mehren M., Heinrich M.C., Eisenberg B., Fletcher J.A., Corless C.L., Fletcher C.D., Roberts P.J., Heinz D., Wehre E., Nikolova Z., Joensuu H. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumours express-ing KIT//J. Clin. Oncol. 2008. Vol. 26 (4). P. 620-625 DOI: 10.1200/JCO.2007.13.4403
  • Blanke C.D., Rankin C., Demetri G.D., Ryan C.W., von Mehren M., Benjamin R.S., Raymond A.K., Bramwell V.H., Baker L.H., Maki R.G., Tanaka M., Hecht J.R., Heinrich M.C., Fletcher C.D., Crowley J.J., Borden E.C. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours expressing the kit receptor tyrosine kinase: S0033//J. Clin. Oncol. 2008. Vol. 26 (4). P. 626-632 DOI: 10.1200/JCO.2007.13.4452
  • Chen L.L., Trent J.C., Wu E.F., Fuller G.N., Ramdas L., Zhang W., Raymond A.K., Prieto V.G., Oyedeji C.O., Hunt K.K., Pollock R.E., Feig B.W., Hayes K.J., Choi H., Macapinlac H.A., Hittelman W., Velasco M.A., Patel S., Burgess M.A., Benjamin R.S., Frazier M.L. A Missence in Kit Kinase Domain 1 correlates with Imatinib resistance in gastrointestinal stromal tumors//Cancer Research. 2004. Vol. 64 (17). P. 913-919.
  • Corless C. Relation for tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001//J. Clin. Oncol. 2010. № 28. P. 15.
  • D’Amato G., Steinert D.M., McAuliffe J.C., Trent J.C. Update on the biology and therapy of gastrointestinal stromal tumors//Cancer Control. 2005. Vol. 12 (1). P. 44-56.
  • Dematteo R.P., Ballman K.V., Antonescu C.R., Maki R.G., Pisters P.W., Demetri G.D., Blackstein M.E., Blanke C.D., von Mehren M., Brennan M.F.,Patel S., McCarter M.D., Polikoff J.A., Tan B.R., Owzar K. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumor: a randomized, double-blind, placebo-controlled trial//Lancet. 2009. Vol. 373 (9669). P. 1097-1104 DOI: 10.1016/S0140-6736-(09)60500-6
  • De Matteo R.P., Gold J.S., Saran L., Gönen M., Liau K.H., Maki R.G., Singer S., Besmer P., Brennan M.F., Antonescu C.R. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)//Cancer. 2008. Vol. 112 (3). P. 608-615.
  • DeMatteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodruff J.M., Brennan M.F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival//Ann. Surg. 2000. Vol. 231 (1). P. 51-58.
  • Debiec-Rychter M., Sciot R., Le Cesne A., Schlemmer M., Hohenberger P., van Oosterom A.T., Blay J.Y., Leyvraz S., Stul M., Casali P. G., Zalcberg J., Verweij J., Van Glabbeke M., Hagemeijer A., Judson I. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours//Eur. J. Cancer. 2006. Vol. 42 (8). P. 1093-1103.
  • Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., McArthur G., Judson I.R., Heinrich M.C., Morgan J.A., Desai J., Fletcher C.D., George S., Bello C.L., Huang X., Baum C.M., Casali P.G. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomized controlled trial//Lancet. 2006. Vol. 368 (9544). P. 1329-1338.
  • Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B.J., Corless C., Fletcher C.D., Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours//N. Engl. J. Med. 2002. Vol. 347 (7). P. 472-480.
  • ESMO Clinical Recommendations for diagnosis, treatment and follow-up. 2010. P. 147-153.
  • Fletcher C.D., Berman J.J., Corless C., Gorstein F., Lasota J., Longley B.J., Miettinen M., O’Leary T.J., Remotti H., Rubin B.P., Shmookler B., Sobin L.H., Weiss S.W. Diagnosis of gastrointestinal stromal tumours: a consensus approach//Human Pathol. 2002. Vol. 33 (5). P. 459-465.
  • Fletcher J., Corless C., Dimitrijevic S. Mechanisms of resistance to imatinib mesylate in advanced gastrointestinal stromal tumors//Proc. ASCO. 2003. № 22. P. 3275.
  • Hasegawa J., Kanda T., Hirota S., Fukuda M., Nishitani A., Takahashi T., Kurosaki I., Tsutsui S., Hatakeyama K., Nishida T. Surgical interventions for focal progression of advanced gastrointestinal stromal tumor during imatinib therapy//Int. J. Clin. Oncol. 2007. Vol. 12 (3). P. 212-217.
  • Heinrich M.C., Maki R.G., Corless C.L., Antonescu C.R., Harlow A., Griffith D., Town A., McKinley A., Ou W.B., Fletcher J.A., Fletcher C.D., Huang X., Cohen D.P., Baum C.M., Demetri G.D. Primary and Secondary Kinase Genotypes Correlate With the Biological and Clini-cal Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor//J. Clin. Oncol. 2008. Vol. 26 (33). P. 5352-5359 DOI: 10.1200/JCO.2007.15.7461
  • Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M., Muhammad Tunio G., Matsuzawa Y., Kanakura Y., Shinomura Y., Kitamura Y. Gain-function mutations of c-kit in human gastrointestinal stromal tumors//Science. 1998. Vol. 279 (5350). P. 577-580.
  • Holdsworth C.H., Badawi R.D., Manola J.B., Kijewski M.F., Israel D.A., Demetri G.D., Van den Abbeele A.D. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor//Am. J. Roentgenol. 2007. Vol. 189 (6). P. 324-330.
  • Joensuu H. Gastrointestinal stromal tumor (GIST)//Ann. Oncol. 2006. Suppl. 10. P. 280-286.
  • Kawanowa K., Sakuma Y., Sakurai S., Hishima T., Iwasaki Y., Saito K., Hosoya Y., Nakajima T., Funata N. High incidence of microscopic astrointestinal stromal tumors in the stomach//Human Pathology. 2006. Vol. 37 (12). P. 1527-1535.
  • Kubota T. Gastrointestinal stromal tumor (GIST) and imatinib//Int. J. Clin. Oncol. 2006. Vol. 11 (3). P. 184-189.
  • Le Cesne A., Ray-Coquard I., Bui B.N., Adenis A., Rios M., Bertucci F., Duffaud F., Chevreau C., Cupissol D., Cioffi A., Emile J.F., Chabaud S., Pérol D., Blay J.Y. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an openlabel multicentre randomised phase 3 trial//Lancet Oncol. 2010. Vol. 11 (10). P. 942-949 DOI: 10.1016/S1470-2045(10)70222-9
  • Le Cesne A., Ray-Coquard I.L., Bui Nguyen B. Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: up-dated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival//J. Clin. Oncol. 2011. Vol. 29. P. 10015.
  • Mazur M.T., Clark H.B. Gastric stromal tumors: Rreappraisal of histogenesis//Am. J. Surg. Pathol. 1983. Vol. 7 (6). P. 507-519.
  • Miettinen M., Lasota J. Gastrointestinal stromal tumours: review on morphology, molecular pathology, prognosis, and differential diagnosis//Arch. Pathol. Lab. Med. 2006. Vol. 130 (10). P. 1466-1478.
  • National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology. 2007. Version 3.
  • Patel S. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibi-tor resistance//Cancer Treat. Rev. 2012. Vol. 38 (5). P. 467-472 DOI: 10.1016/j.ctrv.2011.10.001
  • Ray-Coquard I.L., Bin Bui N., Adenis A. Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: a French Sarcoma Group Study//J. Clin. Oncol. (Meeting Abstracts). 2010. Vol. 28. P. 10032.
  • Rubin B.P., Blanke C.D., Demetri G.D., Dematteo R.P., Fletcher C.D., Goldblum J.R., Lasota J., Lazar A., Maki R.G., Miettinen M., Noffsinger A., Washington M.K., Krausz T. Protocol for the examination of specimens from patients with gastrointestinal stromal tumor//Arch. Pathol. Lab. Med. 2010. Vol. 134 (2). P. 165-170 DOI: 10.1043/1543-2165-134.2.165
  • Singer S., Rubin B., Lux M.L., Chen C.J., Demetri G.D., Fletcher C.D., Fletcher J.A. Prognostic value of kit mutation type, mitotic activity, and histological subtype in gastrointestinal stromal tumors//J. Clin. Oncol. 2002. Vol. 20 (18). P. 3898-3905.
  • Verweij J., Casali P.G., Zalcberg J., LeCesne A., Reichardt P., Blay J.Y., Issels R., van Oosterom A., Hogendoorn P.C., Van Glabbeke M., Bertulli R., Judson I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial//Lancet. 2004. Vol. 364 (9440). P. 1127-1134.
  • Zalcberg J.R., Verweij J., Casali P.G., Le Cesne A., Reichardt P., Blay J.Y., Schlemmer M., Van Glabbeke M., Brown M., Judson I.R. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg//Eur. J. Cancer. 2005. Vol. 41 (12). P. 1751-1757.
Еще
Статья научная
SciUp 2024 © 2024 ©